

1 The technological innovation and tuberculosis
2 elimination: a Technology Foresight study
3

4 Roseli Monteiro da Silva¹

5 ¹Oswaldo Cruz Foundation

6 Orcid: 0000-0002-7184-0256

7 email: roselimonteiro1@gmail.com

8

9 Afranio Kristki²

10 ²Academic Tuberculosis Program, Medical School, Federal University of Rio de Janeiro

11 Orcid: 0000-0002-5900-6007

12 email: kritskia@gmail.com

13

14 Bernardo Pereira Cabral³

15 ³ Federal University of Bahia

16 Orcid: 0000-0001-8242-1244

17 Bernardopcabral@gmail.com

18

19 Martha Oliveira¹

20 Orcid 0000-0002-0064-387X

21 Email: martholiveira@yahoo.com.br

22 ¹ Oswaldo Cruz Foundation

23 **Abstract**

24 In the present study, tuberculosis specialists were surveyed to rate the most effective strategies to
25 eliminate TB as a public health problem by 2050. Then were investigated the most promising
26 emerging technologies for the prevention, diagnosis and treatment of tuberculosis (TB) expected
27 to reach the market by 2035. This Technology Foresight study was specifically carried out by
28 means of a web survey closed questionnaire, which was sent to 29,988 TB specialists worldwide.
29 Of these, 2,657 answers were obtained and analysed. Respondents had demonstrated a high level
30 of academic training (PhD), more than 10 years of professional experience, and a great diversity
31 of both areas of knowledge and geographic reach. In the view of experts, the strategies with the
32 greatest potential impact on epidemic TB were a) shorter time between diagnosis and start of
33 treatment of DS and MDR-TB; b) strengthening tuberculosis control actions in the most
34 vulnerable populations; c) shorter and less expensive regimens for drug resistant MDR/XDR-TB.
35 Regarding the strategies with the highest potential for eliminating TB, our data suggests that the
36 biomedical paradigm is the strongest among the specialists. The most promising technologies
37 expected to reach the market by 2035 selected by the specialists were: (1) new drugs of known
38 chemical classes or new chemical classes; (2) new point-of-care diagnostic tests for DS-TB, drug
39 resistant or multidrug resistant (MDR/XDR)-TB and TB Infection (TBI). We contribute by
40 discussing the most promising technologies and strategies for the elimination of TB in light of
41 social determinants of health models and forecasting studies. We conclude by suggesting that the
42 expected emerging technologies ongoing development will not suffice to end TB by 2050.

43 **Introduction**

44 Tuberculosis (TB) is considered one of today's major public health challenges (1).
45 Despite diagnosis and treatment strategies undertaken in the last decades, a slow decline
46 in incidence has been observed globally and is estimated to have decreased 1.7% per year
47 for the period from 2000 to 2019 (2). In light of this statistic, new technologies are
48 indispensable for decreasing TB incidence and eliminating TB as a public health problem
49 (3-4).

50 According to the Institute for Health Metrics and Evaluation (IHME), the decrease
51 in the incidence of TB worldwide has slowed. Considering the HIV-negative population,
52 the annual rate of reduction of incidence (IRR) decreased from (-1.6%) per year during
53 1990 to 2005 to (-1.3) during 2006 to 2016 (5,6).

54 Given this backdrop, the End TB Strategy (8) with the ultimate goal of eliminating
55 TB as a public health problem by 2050 has become increasingly distant. According to
56 Dye et al. (2013), achieving this goal would require, an incidence reduction rate of around
57 20% per year (7)

58 To understand the underlying mechanisms by which the disease has remained
59 globally and epidemiologically relevant, tuberculosis (TB) experts have recurrently
60 identified several causal elements such as: social inequality, poverty and consequent
61 social vulnerability (9); the epidemiological transition, the increase of chronic diseases
62 and the subsequent increase of susceptibility to TB (10); the high prevalence of
63 tuberculosis infection (TBI) and increased risk of disease reactivation (11–13); the
64 difficulty of accessing the health system (14) and the poor quality of services (15).
65 Finally, another critical factor that has been cited is that healthcare interventions have
66 been rendered technologically obsolete (16, 5).

67 Though the literature has cited the need for technological innovations as
68 interventions for TB, there appears to be no consensual agreement regarding specific
69 research, technological, or innovation foci to target. In fact, the literature suggests at least
70 three different lines of thought regarding the relevance and urgency of new technologies
71 or which technologies should be prioritized for the elimination of tuberculosis.

72 According to the first line of thought, improving access to and quality of care
73 should lie at the forefront, especially in countries with high TB burden. This means that
74 the strategic focus for fighting TB must be on diagnosis and treatment, with emphasis on
75 universal access to the available technological resources (9,14). Such interventions would
76 accelerate the drop of the incidence rate from 7 to 10% per year, which was historically
77 achieved in Europe in the late nineteenth and early twentieth centuries (17). This rationale
78 reinforces the biomedical paradigm for confronting the epidemic, complemented by
79 actions of social protection and governmental commitment. Hence, new technologies are
80 not prioritized in the present and are viewed eventually as part of the future vision of
81 improved care performance (18–20).

82 According to the second line of thought, there is both a need for new technologies
83 as much as for the improvement of individual care. Unlike the first approach, there is a
84 sense of urgency in regards to technological innovation for the elimination of TB (21, 22,
85 3, 23, 5, 24). In the report of the Global Strategy for TB Research and Innovation (25),
86 researchers advocate the imperative need for new technologies, which is given equal
87 emphasis as the improvement of current interventions for the elimination of TB.

88 Finally, experts from a third line of approach claim that elimination can only be
89 achieved with new technologies capable of reducing the prevalence of TBI
90 (screening/screening and prognostic tests, new treatments, therapeutic vaccine) and/or a
91 new vaccine(s) capable of preventing disease, targeted at young adults and adolescents

92 (13, 1, 12, 11, 26, 27). It is worth mentioning that since TB is a disease of respiratory
93 transmission, the scientific community has increasingly come to the understanding that
94 the current control actions are insufficient to interrupt the chain of transmission (4).

95 Against this backdrop, the present study sought, 1) to identify from the viewpoint
96 of TB specialists, the medical-sanitary strategies with the greatest potential impact on the
97 epidemic, regardless of the current status of technological development, 2) to prospect
98 the most promising technologies to reach the market by 2035 and their potential
99 contribution to the elimination of TB by 2050.

100 **Method**

101 To answer the research questions, a future study was conducted, by means of the
102 methodological approach known as Technology Foresight (TF). Technology Foresight
103 studies have been carried out since the 1990s in a systematic way in several countries,
104 mainly in Europe and Asia, as support programs for long-term governmental decision
105 making on public policies in science and technology (28).

106 In the healthcare sector, foresight studies have explored future possibilities for
107 therapies that still pose medical challenges, for instance: (a) the future of cancer care (29);
108 (b) new Treatments for cystic fibrosis (CABRAL et al, 2022); (c) future of genetic
109 therapies for rare genetic diseases (BRAGA et al., 2022) (d) probing expert opinions on
110 the future of kidney replacement therapies (CABRAL et al, 2020).

111 TF, as explained by Haghdoost et al. "... is a process that takes a systematic long-
112 term look at science, technology, economy, and society in the future (6); it also seeks to
113 identify areas of strategic research and emerging technologies, which seem to result in
114 valuable socioeconomic advantages for the society" 30 (2).

115 Developed by researchers from the Science Policy Research Unit (SPRU) /Sussex
116 University (31–34), TF is based on the assumptions and concepts of innovation
117 economics, represented by neo-Schumpeterian principles (35). Within this framework,
118 innovation is conceived as a phenomenon of intrinsically economic nature and the main
119 driver of economic and social development. Accordingly, Linstone (2011)’s historical
120 analysis identifies three eras of technological development and their socioeconomic
121 impact: (a) industrial, (b) information technology, and the molecular era. For the author,
122 the latter has begun in the mid-1990s, characterized by innovation in biotechnology,
123 material sciences and nanotechnology, presenting the biggest opportunity for fighting TB.
124 (36).

125 In TF, it is assumed that the future cannot be scientifically demonstrated from
126 certain assumptions. The goal is to address the chances of realization and the options for
127 actionable strategies in the present (37). The exercise of anticipation should be backed by
128 explicit consideration of future possibilities and allow for freedom of thinking. By
129 surpassing routine and preconceived barriers, the approach aims to identify points outside
130 the trend curve - sentinel events – which are indicative of changes or opportunities for
131 innovation.

132 With the intention to capture the perception/vision of innovation agents and other
133 stakeholders about the technological future, TF uses the flexible combination of several
134 social research tools. In this study, we specifically used a closed questionnaire, applied
135 virtually to researchers around the world, through the platform *Survey Monkey*®.

136 Invited survey participants and their e-mail addresses were obtained from
137 scientific publications indexed in *Web of Science* (WoS), through the *tesaurus* TS =
138 “tuberculosis” or “tuberculoses” or “Koch disease” or “Koch’s disease” or

139 “*Mycobacterium tuberculosis*” (via Capes¹). A total of 43,087 scientific documents and
140 29,988 researchers were identified for the selected period of 2015 to 2020. Their email
141 addresses were extracted from the scientific publications using a Python script, developed
142 by the Prospective Studies Group of Fiocruz. Invitations were sent as well as answers
143 were collected between October and December of 2020.

144 The development of the survey instrument involved an extensive literature review,
145 thematically covering: (1) social determinants and epidemiology of TB (46 documents);
146 (2) expectations about the future of the epidemic (28 documents), (3) emerging
147 technologies in vaccines (31 documents), diagnosis (36 documents), and treatment of TB
148 (22 documents). The review included original scientific articles, review articles, scientific
149 letters and editorials, and technical reports from international organizations specialized in
150 TB.

151 The questionnaire was composed followed questions (1) strategies of greatest
152 potential impact for the elimination of tuberculosis, **regardless of their current**
153 **technological feasibility**; (2) most promising technological solutions to reach the market
154 by 2035; (3 to 7) specific technologies most promising in vaccines, diagnostic tests and
155 treatment, to reach the market by 2035. For these questions, respondents were asked to
156 assign scores from 1 to 5 for the alternatives presented, being (1) the least promising
157 technology and (5) the most promising technology.

158 All questions highlighted the 15-year timeframe (from 2020 to 2035) for new
159 technologies to reach the market, with the perspective of eliminating TB as a public health
160 problem by 2050.

¹ CAPES – Coordination for the Improvement of Higher Education Personnel, Ministry of Education of Brazil.

161

162 **Ethics statement**

163 Confidentiality and privacy were described to all participants prior to enrolment in the
164 study. All data was anonymized, without possibility of participant's identification. Such
165 security is guaranteed by the software itself. All participants provided consent by the
166 enrolment in the study (See supplementary information – Introduction page).
167 Participation was voluntary and was not stimulated by any gains. Participants were free
168 to give up at any time and an information contact was made available for any questions
169 or issues. The application of the questionnaire did not involve any direct contact between
170 researchers and the participants.

171 **Respondents' characteristics**

172 Of the 29,988 invited researchers, 2,711 (9.0%) agreed to participate in the survey
173 and answered the questionnaire. We obtained 2,567 valid answers², of which 69.2% were
174 complete.

175 Regarding the characteristics of the respondents, the vast majority (95.5%)
176 reported having a post-graduate degree, with 76.4% holding a doctorate. Considering
177 areas of knowledge, 35% of respondents reported having knowledge in basic science
178 areas - microbiology, genetics, immunology; 24% in clinical areas - infectiology,
179 pneumology - and 20% in public health and epidemiology.

180 Regarding professional activity, respondents were mainly affiliated with teaching
181 and research institutions - only 2% reporting working in industry. About 33% reported
182 working in basic research, 17% in public health, 14% in clinical research, 12% in

² Respostas dos especialistas que manifestaram ter conhecimento sobre o objeto da pesquisa

183 epidemiology, and 6% in translational research. About 2/3 of the respondents declared
184 professional experience of more than 10 years. Finally, regarding geographical origin,
185 31% reported being from Asia, 23% from Europe, 16% from South America, 15% from
186 Africa, and 14% from North America.

187 **Results**

188 Regarding the strategies with the greatest potential impact on the epidemic, the
189 highest proportion of grade 5 were attributed to: (1) reducing the time between diagnosis
190 and initiation of treatment (61%), (2) strengthening control actions in vulnerable
191 populations (59.9%), and (3) reducing the cost and time of MDR-TB treatment (50.1%).

192 Considering that TB has distinct epidemiological characteristics among
193 geographic regions, the data were also consolidated and analysed according to the origin
194 of the researchers.

195 Small regional differences in the hierarchy of the most valued alternatives were
196 observed. While researchers from the Americas tended to more value strengthening
197 control actions for more vulnerable populations, researchers from other continents rather
198 prioritized reducing the time between diagnosis and treatment initiation. Researchers
199 from Australasia considered reducing the prevalence of TBI alongside reducing the cost
200 and time to treatment of MDR-TB as factors of the greatest potential impact. For
201 researchers from South America, increasing social protection actions was among the three
202 strategies with the greatest potential impact, differing from the other researchers. Another
203 interesting difference was the higher value placed on shorter treatment regimens for TB-
204 DS for researchers from Australasia and Africa. HIV prevention was also of importance
205 for researchers from Africa (Figure 1).

206 This is Figure 1 - File name Survey_ Figure 1 Strategies.

207 **Figure 1 - Strategies with the greatest potential impact on tuberculosis, according**
208 **to the respondent's origin.**

209 Among the most promising technological solutions to reach the market by 2035, new
210 drugs for MDR/XDR treatment (39.6%) and new point-of-care diagnostic tests (39.2%)
211 received the highest ratings. In third place, new drugs or the repositioning of drugs for
212 treating TB-DS (38.3%) were considered most promising. Only 26.3% of respondents
213 considered the possibility of a new vaccine by 2035 as highly promising. Slight
214 variations in the hierarchy of the most promising technological solutions were also
215 observed depending on the origin of the respondent (Figure 2).

216 This is Figure 2 - File name Survey_ Figure 2 Technologies

217 **Figure 2 - Most promising technological solutions to reach the market by 2035,**
218 **according to the origin of the respondents.**

219 For researchers from Europe and Asia, new drugs for the treatment of MDR/XDR-
220 TB were considered the most promising, while researchers from South America and
221 Australasia considered new drugs for DS-TB as the most promising. Researchers from
222 North America and Africa pointed to new point-of-care diagnostic tests as most likely to
223 reach the market by 2035.

224 Regarding the specific technological platforms for the development of new TB
225 vaccines, the respondents rated the alternative that assumes an integrated technological
226 platform, capable of combining various techniques and knowledge in vaccinology, as
227 proposed by Zenteno-Cuevas³, enabling the complete design of a new vaccine, on new

³ This new concept of vaccinology encompasses the utilization and integration of diverse fields and techniques of study, including reverse vaccinology, immunogenomics, immunogenetics, systems biology, immune profiling, proteomics, whole genome sequencing, transcriptomics, host-pathogen interaction, bioinformatics, and computational modeling (p.5).

228 technological bases (26.8%) as most promising (38). This was followed by the adoption
 229 of a new route of administration (17.9%), and lastly, a new vaccine using live attenuated
 230 organisms inactivated vaccines and recombinant vaccines, including viral vectored
 231 (16.7%) (Figure 3).

This is Figure 3 - File name Survey-Figure 3. - Vaccines

Figure 3 - Most promising technological platforms for the development of a tuberculosis vaccine by 2035.

235 Regarding the development of new point-of-care diagnostic tests, the respondents
 236 consider the nucleic acid amplification platform (NAAT) by PCR as most promising (
 237 38.4%); the new generation of target genomic sequencing (T-NGS) or a whole-genome
 238 sequencing (WGS) came in second with 32.9% and in third place the host biomarkers
 239 based on "omics technics" (RNA-signature, Micro RNA, metabolomics, proteomics) with
 240 21.1% (Figure 4).

This is Figure 4 - File name Survey_ Figure 4_ diagnostic tests

Figure 4 - Most promising technological platforms for the development of new point-of-care diagnostic tests for tuberculosis by 2035.

244 Regarding the treatment of all forms of TB, new drugs based on new chemical
 245 classes were considered the most promising platform for the treatment of all clinical forms
 246 of TB (Table 1). Specifically, for TBI, therapeutic vaccines and immunotherapy with
 247 various biological agents (peptides, monoclonal antibodies, interferon). However, for
 248 both TB-DS and TB-DR, new drugs from already known chemical classes were
 249 considered most promising in second place.

	New drugs (new chemical classes)	New drugs (known chemical classes)	Repositioning of drugs	Host direct therapy (vaccines)
TBI	(1°) 23,8%	(4°) 19,6%	(5°) 18,7%	(2°) 23,3%

TB-DS	(1°) 30%	(2°) 25,9%	(3°) 22,9%	(4°) 20,9%
TB-MDR	(1°) 40%	(2°) 33,9%	(5°) 24,9%	(6°) 20,5%

250 **Table 1 – Most promising technology platforms in tuberculosis treatment to reach**
251 **the market by 2035.**

252 **Discussion**

253 **Strategies with the greatest potential impact for eradicating** 254 **tuberculosis by 2050**

255 The TB specialists who answered the survey considered strategies oriented
256 towards improving diagnosis and treatment as those with the greatest potential impact on
257 the TB epidemic. Moreover, the intensification of actions targeting the most vulnerable
258 populations was ranked as the second most important factor. It was observed that
259 interventions of a preventive nature - reducing the prevalence of TBI (36.6%), population
260 screening to identify individuals at high risk for the development of TB disease (36.0%)
261 and increasing population immunity (26.8%) - were the least valued strategies.

262 This response profile reinforce that those researchers are highly driven by the
263 biomedical paradigm. This paradigm is represented by the seminal idea that "TB
264 prevention begins with cure" (STYBLO & BUMGARNER (9). It assumes that the proper
265 diagnosis and treatment of patients (cure), would reduce mortality, prevalence and, on an
266 ongoing basis, incidence (39).

267 This same paradigm is present in several scientific and technical documents of
268 literature specialized in TB (4). In the guidelines of the End TB Strategy (2015), for
269 example, the first pillar - Patient-Centred: Care and Prevention, specifically expresses
270 more than the importance of care and cure, but additionally emphasizes prevention within
271 appropriate diagnosis and treatment of cases (WHO, 2015). In the same sense, Lönnroth
272 et al. (2009) reinstate that the main challenge of TB control is to ensure globally adequate

273 access to diagnosis and treatment (9). They point out that options to include preventive
274 efforts have not yet been fully considered.

275 Thus, the priorities selected by the specialists appear to lie within the biomedical
276 paradigm, in line with KUHN's (1998) premise:

277 “The commitments that govern normal science specify not only
278 what sorts of entities the universe does contain, but also, by
279 implication, those that it does not.” [40 \(26\)](#)

280 It is worth emphasizing that the biomedical paradigm does not deny the existence
281 of social factors that interfere with contracting TB. Only, such conditions are treated as
282 externalities and not as part of a complex process of social production. Therefore, it is not
283 paradoxical that the strengthening of control actions aimed at the most socially vulnerable
284 population groups has been listed among the most prioritized actions. Notably, no specific
285 epidemiological studies were found on the potential effects of this strategy, nor on new
286 drugs for the treatment of MDR-TB for the elimination of TB.

287 Moreover, prospective studies based on Technology Forecast [\(31\)](#), have indicated
288 opposite expectations regarding specialists' responses about the potential impact of new
289 strategies and technologies for TB elimination.

290 Dye et al (2013) estimate that reducing the time between diagnosis and the
291 beginning of treatment would have an impact on the order of 28% in reducing the
292 incidence of TB over a 35-year time span (3). Regarding the high prevalence of TBI, the
293 authors point out that even if TB transmission were totally interrupted in 2015, the
294 existing pool of infected persons would still generate more than 110 cases per million
295 population in 2050 (hypothetical case of 1100 new cases per million/year). On the other
296 hand, if only 8% of individuals infected with *M. tuberculosis* were permanently protected

297 from the disease each year, the incidence could drop to 90 new cases per million. If the
298 intervention reached 14% of those infected, the incidence could drop to 20 cases per
299 million by 2050.

300 According to Abu-Raddada et al (2009), reducing the treatment time for TB-DS,
301 would also have a limited effect on incidence, with an estimated reduction of 8.3%;
302 19.3%; 22.9% with shortening of the therapeutic regimen to 4 months, 2 months, and 10
303 days, respectively (41).. On the other hand, the authors estimate that neonatal vaccination,
304 considering the portfolio of vaccines listed in the study, could decrease the incidence of
305 tuberculosis by 39% to 52% by 2050. They point out that a vaccine targeting adolescents
306 and young adults would have a greater and faster epidemiological impact than vaccination
307 of neonates, an estimated 80% reduction in incidence by 2050 (41).

308 On the other hand, based on the model of social determinants of health (SDH),
309 derived from the Public Health paradigm, it is possible to unveil an explanatory network,
310 organized in layers of intertwined causal processes, involving from macro elements of
311 the social production of the disease to its "natural" history, at the level of each individual.

312 It is noteworthy that TB has benefited nowadays from the negative effects on
313 health, stemming from the urbanization process (agglomerations) that favor transmission
314 and from the modern lifestyle (increase in chronic non-communicable diseases, including
315 mental illness and drug addiction) that increase the risk of contracting TB (42).

316 The slow reduction in the incidence and increase in the proportion of MDR-TB
317 has demonstrated that current control actions are progressively losing effectiveness and
318 that there is a great need for new interventions primarily oriented towards prevention of
319 illness, early detection, and reduction of the pool of infected people.

320 Schrager et al. (2020) reaffirm that only a new vaccine with the ability to prevent
321 tuberculosis, targeted at adolescents and young adults, could effectively contribute to
322 reducing incidence. If introduced by 2025, such a new vaccine could result in a drop in
323 incidence of nearly 17% per year, effectively paving the way to eradication (43). In
324 addition, for several authors, immunization would be one of the most effective strategies
325 to address bacterial resistance, since the genetic sites of immunity are distinct from those
326 that generate drug resistance (38).

327 In a prospective epidemiological study on the potential impact of a new vaccine,
328 Harris et al. (2020), estimated that the expected reduction of incidence (IRR) in this period
329 would be 51%, 52%, and 54% respectively for China, South Africa, and India, using 10
330 years of massive vaccination campaign, directed to adolescent population and an efficacy
331 of 70% in preventing the disease as parameters (26). According to the authors, preventive
332 action targeted only at the infected population would have a greater and faster impact,
333 considering the goal of eradicating the disease by 2050.

334 On the other hand, in closeness with the public health paradigm, researchers such
335 as Zenteno-Cuevas (2017), Schrager (2018,2020), Keshavjee (2019), Ole F Olesen
336 (2019), Roland Diel (2013), Philippe Glaziou (2013), Holmes (2017); Barry Bloom and
337 Ranif Atun (2013), Helen McShane (2011), advocate the need for new strategies, in
338 particular aimed at reducing the huge contingent of infected (TBI) and preventing the
339 active disease in the general population. However, even today a minority of experts
340 support this view.

341 A second line of explanation for these results may be related to the tendency
342 observed in TF exercises, that respondents should be captured by current problems, rather
343 than theoretical reflection on future possibilities. The empirical, tangible reality

344 sometimes imposes itself over an abstract, future-oriented logic. Thus, the focus on
345 interventions with long-term epidemiological impact are displaced by the need for short-
346 term care solutions.

347 Bonaccorsi et al, from the cognitive psychology and decision theory paradigm,
348 poses the possibility of the occurrence of cognitive bias in technology foresight exercises
349 conducted with experts only (44). According to this paradigm, competence to make
350 judgments and decision making processes depend on memory capacity and the nature of
351 the information being processed.

352 “People do not perform exhaustive search and analysis of alternatives, but
353 rather use well-functioning (but not optimal), rules of thumb (*heuristics*), and
354 are subject to systematic distortions (*biases*) in their judgments (particularly,
355 probability judgments) and decisions. (44) (2)

356 The participation of several stakeholders in foresight exercises is a seminal
357 recommendation as a strategy to prevent biases. For technical-operational reasons, in this
358 study, the exercise was conducted only with TB experts.

359 Aiming to mitigate the occurrence of this type of bias, Bolger and Wright (2017)
360 suggest the application of multiple techniques - a process called expert knowledge
361 elicitation (EKE) that makes it possible to confront, at different analytical stages,
362 information from several sources (45). In this research, forecast studies and literature
363 review data were used as analytical counterpoints to the research findings.

364 Such limitations, however, do not invalidate the method, nor its results. It only
365 indicates that the future may result from this dominant thinking, in this case, linked to a
366 biomedical view of the problem.

367 It is important to stress that the specialists' choices may be able to solve important
368 problems in clinical practice, which, on its own, is remarkable. Nevertheless, bearing in

369 mind the expected reduction in the incidence of TB, we believe that such priorities will
370 have little impact on the elimination of TB.

371 **Most promising technological solutions to reach the market** 372 **by 2035**

373 Most respondents reported that point-of-care diagnostic tests and new drugs for
374 MDR-TB would be the most promising technologies to reach the market by 2035. Given
375 the very close scores (39.6% and 39.2%), the results suggested that the experts' highest
376 innovation expectations were also focused on diagnosis and treatment. New drugs for
377 treating TB-DS was the third technological solution with the greatest potential to enter
378 the market.

379 There was also a rather skeptical attitude toward the emergence of new TB
380 vaccines and prognostic tests for individuals with TBI. Indeed, as discussed in a later
381 section on new diagnostic technologies, significant technological advances in the last 10
382 years have made the field quite dynamic (42). NAAT Technology-based diagnostics have
383 incorporated incremental innovations that bring new products closer to the ideals of point-
384 of-care diagnostics and operational simplification (46). A technological path that adds to
385 PCR-based nucleic acid amplification other technologies such as microfluidics,
386 biosensors, and nanotechnology is already feasible.

387 This phenomenon has not been observed in the vaccine area, except for the use of
388 technological platforms focused on the production of protein subunits, the most used in
389 the development of several vaccine candidates. Other technological platforms such as
390 recombinant or inactivated vaccines have also not been able to open a path of innovations.
391 In the drug area, the most recent technological development also shows promising results

392 with new molecules from new chemical classes. At least 18 new drugs from this category
393 are in phase III of clinical trials (47).

394 This evidence, in the light of the postulates of the Economics of Innovation,
395 suggests that the resources, the interests of public and private innovation agents, and the
396 processes of interaction and learning have proven to be more effective in the diagnostic
397 area. It is worth remembering, in the neo-Schumpeterian line of thought, that
398 technological innovation is:

399 1) a continuous and cumulative process, involving not only incremental and
400 radical innovation, but also its diffusion, appropriation, and use (48) ;

401 2) a process involving interactive learning and accumulation of knowledge,
402 which takes place in connection with ongoing activities in production and
403 sales (48) ;

404 3) institutions, in different innovation systems, affecting the nature of these
405 interactions between people and customs, which, in part, may explain the
406 accumulation or non-accumulation of learning processes (49)

407 4) intensive learning processes can be converted into technological innovation
408 avenues or technological pathways (49, 50)

409 Thus, as an economic phenomenon, it is likely that technological innovation in
410 diagnosis has been recognized by innovation agents in industry, governments, research
411 organizations, and the financial system as more timely and promising --~~A~~all this with the
412 proper scientific backing of the biomedical paradigm.

413 It should be noted that technology is itself a body of knowledge about certain
414 classes of events and activities, and not a mere application of knowledge brought from
415 another field. The normal situation in the past, and to a considerable degree also in the

416 present, has been that technological knowledge precedes scientific knowledge (e.g. BCG
417 vaccine) (51).

418 **Most promising vaccine technologies (to 2035)**

419 The technological platform most valued by respondents for developing a new
420 tuberculosis vaccine corresponds to the approach proposed by Zenteno-Cuevas (26.8%),
421 defined as follows:

422

423 This new concept of vaccinology encompasses the utilization and
424 integration of diverse fields and techniques of study, including
425 reverse vaccinology, immunogenomics, immunogenetics,
426 systems biology, immune profiling, proteomics, whole genome
427 sequencing, transcriptomics, host–pathogen interaction,
428 bioinformatics, and computational modelling. 38 (5)

429 However, the scattering of the values assigned to the listed alternatives was
430 observed. This, even considering the integrated technological platform proposed by
431 Cuevas obtained 8 percentage points above the second option (new routes of
432 administration - 17.9%) and double the score received by the inactivated vaccine
433 technology (11%), considered the least promising of the technologies.

434 In the Pipeline Report Tuberculosis Vaccines 2021, there are 15 vaccine
435 candidates listed, which are in clinical trials, distributed from the technological point of
436 view in: a) inactivated/fragments (3); b) attenuated MTB (1); c) protein subunits (5); d)
437 viral vector (3), e) BCG (2) (52). No candidates in this portfolio have been developed
438 based on an integrated or mRNA/DNA platform (52).

439 Mike Frick, in an introductory text to this report, offer an interesting reflection on
440 the dynamics of technological development in the area of tuberculosis vaccines,
441 compared to the results achieved against COVID19.

442 While the technological development time was measured in months to obtain 20
443 vaccine candidates during the COVID19 pandemic, the technological development time
444 used for TB – a disease that kills more than 1 million people per year – is measured in
445 centuries.

446 Nowhere to be found is the tool that would reduce TB incidence in time
447 to realize the World Health Organization’s vision of eliminating TB by
448 2030: a new vaccine (or multiple vaccines) that protects adolescents and
449 adults against TB. The confluence of the BCG centenary and the advent
450 of COVID-19 vaccines begs the question: why are there no new
451 vaccines against TB? 52 (1).

452 The author points out the large volume of resources applied (about 11 times what
453 was applied in TB in the last decade) and the regulatory changes, which enabled the
454 parallel achievement of some stages of technological development as main factors related
455 to the success of this technological innovation process.

456 In addition, Frick highlights the key role of governments and funders in the proper
457 direction of resources in the promotion of this process. This explanation brings us back
458 to the innovation ecosystem approach, where innovation is the result of the push of
459 demands arising from public health policies into the market. According to LI, GARNSEY
460 (2014) "This requires new sources of funding and new relationships between public sector
461 organizations, philanthropic trusts, medical foundations and entrepreneurial innovators"
462 53 (1). In the history of technological development of TB vaccines, we highlight some
463 lessons learned:

464 - Immunity produced by the classical T-lymphocyte induction pathway is not sufficient
465 to produce protection against TB. Vaccines with a single dominant antigen, as a booster
466 to BCG, do not seem to be as effective as expected. This has somewhat called into
467 question technologies based on protein subunits and viral vector (Bloom and Lambert,
468 2016).

469 - Bacillus' containment is a more tangible goal from a technological perspective than
470 preventing primary infection or sterilizing the granuloma (54).

471 - Adolescents and young adults should be the preferred population group for a new
472 vaccine, considering the goal of TB elimination (26).

473 - Several vaccine schemes should be considered in the process of developing a new
474 vaccine (55).

475 - New vaccines are probably the best strategy for tackling MDR-TB (27).

476 The M72/AS01E (GSK) vaccine, protein subunit-based (containing Mtb32a-
477 Mtb39a dormancy phase antigens), is the closest candidate to reach the market by 2035
478 (27). The efficacy observed in phase II studies is 54%. This may mean that we are still
479 far away from a new widely effective TB vaccine, in accord to expectation of the
480 respondents.

481 **Diagnosis and prognosis of tuberculosis**

482 The technologies that had the highest scores from experts for point-of-care TB
483 diagnosis were those based on nucleic acid amplification (38.4%) by polymerase chain
484 reaction (PCR) and new generation of gene sequencing (WGS or T-NGS) (32.9%).

485 Two issues should be considered when analyzing these results. First, incremental
486 innovations in NAAT technology have been running for more than 20 years, with a

487 number of new products becoming available on the market, including LoC devices that
488 do not require a laboratorial environment or even electrical power (56).

489 In fact, NAAT is one of the most promising technologies to become an effective
490 point-of-care diagnostic tool, progressively more accessible, simultaneously meeting the
491 demand for diagnosing tuberculosis and mapping the profile of bacterial resistance.

492 At present, several products are available on the market and are being
493 recommended by the WHO: Gene Xpert ULTRA, Truenat MTB plus, Easy NAAT
494 MTBC, FluoroType® MTB (RT-PCR), BD Max MDR-TB (57). The VereMTB Test, in
495 Lab-on-a-chip device by Veredus (Singapore), is under validation within research
496 laboratories (42). The rise in market competition for the new tests should contribute to
497 cost reduction and further diffusion of the technology to poorer countries.

498 The new generation of gene sequencing (WGS) used to study DNA from isolated
499 *M. tuberculosis* although highly valued by respondents, applies more to Mtb genomic
500 surveillance than to clinical practice. On the other hand, the use of T-NGS in clinical
501 samples has an advantage because other than the potential of miniaturization and low
502 operational cost, with the use of metal-oxide semiconductors and PCR reagents in very
503 few quantities, the use of T-NGS can allow for TB-MDR/XDR diagnosis in 2 to 3 weeks
504 (58).

505 However, none of these technologies are applicable to the diagnosis of TBI,
506 remaining a serious obstacle to clinical practice and TB epidemiological control measures
507 because they do not extend the diagnostic capacity in people with immunodeficiency,
508 chronic diseases and in children by using sputum as a biological sample (46). Prior TBI
509 testing is recommended for HIV-uninfected contacts over five years of age, as TPT is
510 more likely to benefit those with positive tuberculin skin tests (TST). TST with PPD Rt-

511 23 has low specificity in BCG-vaccinated populations and chain distribution limitations.
512 Interferon-gamma release assays (IGRA) are acceptable alternatives, but the costs and the
513 need for laboratory infrastructure are a matter of concern. New TSTs, using recombinant
514 ESAT6-CFP10 antigen proteins, which include C-Tb (AJVaccines, Denmark, to be
515 transferred to Indian Serum Institute), Diaskin Test® (Diaskin, Generium, Russian
516 Federation), EC-test (Anhui Zhifei Longcom, China) have been developed to increase
517 specificity in laboratory-free settings and recently recommended by WHO (59).

518 Host molecular biomarkers appear as the third most promising technologies
519 (21.1%). The recent discovery of the ability of these markers to discriminate individuals
520 with active TB from healthy individuals and with TBI (60–62), probably opens new
521 routes of technological development (63).

522 MacGregor-Fairlie et al. (2020) note that TB diagnosis has been through several
523 transformations, including the use of part of the bacillus (rather than the whole bacillus)
524 in direct diagnosis and, most importantly, the introduction of indirect methods related to
525 the host immune response profile (46).

526 Nevertheless, these technologies were considered less promising by the
527 respondents. Point-of-care testing has the possibility of radically changing the method of
528 laboratory production, specifically through means of decentralized approach and without
529 a large technical equipment. The central laboratory may be replaced by a chip in the
530 future, distributed throughout the primary health care network.

531 Two explanatory hypotheses can be raised in relation to these results. First, the
532 medical tradition in the area of TB reinforces the need to identify the bacillus in order to
533 make a diagnosis. Either due to the complexity of the disease or the need for differential
534 diagnosis, it is plausible to assume a bias in this perception. A distorted perception that

535 distinguishes tuberculosis from other infectious diseases with regard to technical
536 requirements to the diagnostic and treatment processes.

537 The second aspect refers to the relevance given more to the diagnosis of clinically
538 active disease than to the detection of TBI or increased risk of disease (prognosis). The
539 biomedical paradigm prevails in the experts' expectations.

540 The use of host biomarkers for the diagnosis of TBI and risk of illness (TBI/TB)
541 could contribute to the control of the epidemic insofar as they make it possible to direct
542 preventive treatment or the use of a therapeutic vaccine. This aspect is highlighted in the
543 WHO report on research and technological development (2020), reiterating the need for
544 increasing investments in this sector (WHO, 2020).

545 It is crucial to note that such strategic directing would face significant trade
546 barriers due to competition and eventual replacement of NAAT-based technology.

547 **Treatment of Tuberculosis**

548 Most respondents considered new drugs from new chemical classes as most
549 promising for TB treatment, regardless of the clinical form (TBI or active TB) or the drug
550 resistance status (DS or DR/MDR). In the case of TBI, however, host direct therapy, by
551 means of vaccines, was considered the second most promising option and with very close
552 value to new drugs in new chemical bases.

553 For TB-DS, drug repositioning still appears as the third most promising
554 technological option. For MDR-TB, new drugs in new chemical classes was the
555 proportionally most valued alternative, with 40% of the responses scoring (5).

556 Currently there are 30 drugs in various stages of preclinical and clinical
557 development (47). Of this list, twelve are new drugs from known chemical classes, with

558 or without a lead drug. Eighteen constitute new chemical structures with new mechanisms
559 of action. Of the drugs in phase 2-3 of technology development, seven are new drugs from
560 new chemical classes and three from known chemical classes, which demonstrates the
561 strength of the technology development arena⁴.

562 These data support the experts' choice of drugs from new chemical classes as the
563 most promising solution for the treatment of TB. For TBI, the immunotherapy strategy
564 through vaccines still constitutes a technological challenge.

565 **Conclusion**

566 The biomedical paradigm constitutes the main anchor that sustains current
567 strategies of intervention on the TB epidemic. This thinking has been reflected in the
568 prioritization of new strategies, which still prioritize a future focused on diagnosis and
569 treatment as having the greatest potential impact on the control and eventual elimination
570 of TB.

571 Strategies and technologies aimed at preventing TB illness (preventive vaccines)
572 and eliminating the TB contingent (diagnostic and prognostic tests, preventive treatment
573 and/or immunotherapy) were the least valued by respondents, reiterating the dominance
574 of biomedical thinking among experts.

575 The technological solutions considered most promising also focus on TB
576 diagnosis and treatment - new diagnostic tests and new drugs for MDR TB. Given the
577 likely materialization of this forward-looking vision, it is possible that new technologies
578 will have little or no effect on the elimination of TB as a public health problem by 2050.

⁴ https://www.newtbdrugs.org/pipeline/clinical?field_advancing_value=All, Access on: 08/07/2022

579 Technological developments in new vaccine development show a reduction in the
580 use of the recombinant BCG-based platform and an increase in those vaccines based on
581 protein subunits. The most promising technological platform, however, in the
582 respondents' view would be based on a new paradigm, which comprises the integrated
583 application of various areas of knowledge and techniques in vaccinology. Nevertheless,
584 no vaccine candidates from the Pipeline Report 2021 for clinical trials, have been
585 developed based on this paradigm (52).

586 The most promising technologies in TB diagnostics do not meet the demands for
587 differential diagnosis (TBI and TB), nor do they have prognostic value on the risk of
588 progression from TBI to clinically active disease (TB), or markers for treatment
589 monitoring. Such elements are considered, from a public health point of view, essential
590 for the elimination of the disease. Once again, the issue of governmental involvement
591 pulling into the market (demand pull) innovations that meet public health demands seems
592 to be fundamental for the development of new products of interest to public policies.

593 Technological trends recorded in the literature point to host biomarkers as one of
594 the most suitable solutions for point-of-care diagnosis of TB and TBI. However, the
595 economic dynamics for developing this technology do not seem to benefit biomarker area.
596 It is also worth noting that although some of these biomarkers have been available since
597 2018, there has not been a WHO endorsement recommending this technology for new
598 product development.

599 In summary the most promising specific technologies in the area of TB vaccines,
600 diagnostic tests and treatment were respectively:

601 (1) an integrated technology platform enabling the application of the various fields
602 of knowledge and techniques in vaccinology, including reverse vaccinology,

603 immunogenomics, immunogenetics, biological systems, immune profiling, proteomics,
604 whole genome sequencing, transcriptomics, bacillus-host interaction, bioinformatics,
605 computational modelling.

606 (2) new diagnostic tests based on nucleic acid amplification technology (NAAT)
607 and next generation gene sequencing (NGS).

608 (3) new drugs from new chemical classes for all forms of TB. For ILTB
609 immunotherapy using vaccines was considered the second most promising technology.

610 **Recommendations**

611 In light of the study results, we recommend a strategic redirection of tuberculosis
612 R&D efforts toward technologies for which the greatest potential impact on the incidence
613 of tuberculosis is expected, with a view to its elimination as a public health problem by
614 2050.

615 To this end, firstly it is deemed necessary to strengthen and disseminate a
616 comprehensive vision of the tuberculosis epidemic, so that the fight against the disease is
617 adequately oriented to its network of causalities, in a contextualized manner.

618 Such an approach should also enable a greater consensus in the scientific
619 community regarding the role of technological innovation, and priorities in DT and
620 Innovation, as an indispensable element of the effort to eliminate the disease.

621 From a pragmatic point of view, the results from this study suggest that the
622 resources and efforts of technological development and innovation should be directed to
623 the generation of:

624 - new diagnostic and prognostic tests that enable the screening of the population
625 with ILTB and identification of those at high risk of developing the disease. From the
626 technological standpoint, this means investing in omics technology platforms aiming at
627 the creation of host biomarkers capable of differentiating the clinical forms of the disease;

628 - new point-of-care diagnostic tests for tuberculosis also based on omics
629 technology, preferably replacing sputum as the biological sample.

630 - new preventive vaccines directed especially to the adolescent and young
631 population, infected or not by M. tuberculosis.

632 Such an approach implies directing resources especially to clinical and
633 translational studies, with emphasis on

634 - multicentre phase (I, II, and II) clinical trials from the current portfolio of TB
635 vaccine candidates. Although many vaccines are ready for human clinical trial, this stage
636 has not yet been initiated.

637 - clinical studies on the effect of therapeutic vaccines aimed at increasing efficacy,
638 reducing the time of treatment of MDR-TB or decreasing the number of drugs applied;

639 - technological development and clinical studies in host molecular biomarkers,
640 with the perspective of building point-of-care devices capable of recognizing the clinical
641 forms of tuberculosis, bacterial resistance, and also providing prognostic vision.

642 Through these suggested processes, the role of governments in the appropriate
643 allocation of resources for research and innovation becomes more critical.

644 **References**

- 645 1. Bloom B, Atun R. Back to the future: Rethinking global control of tuberculosis. *Sci Transl*
646 *Med* 2016; 8(329):329ps7.
- 647 2. WHO. Global tuberculosis report 2020; 2020.
- 648 3. Holmes KK, Bertozzi S, Bloom B, Prabhath. J., editors. Disease Control Priorities: Major
649 Infectious Diseases [Capítulo 11 Tuberculosis]. (vol. 6).
- 650 4. Pai M, Furin J. Tuberculosis innovations mean little if they cannot save lives. *eLife* 2017:1–9.
- 651 5. GBD Tuberculosis Collaborators. The global burden of tuberculosis: results from the Global
652 Burden of Disease Study 2015. *Lancet Infect Dis* 2018; 18(3):261–84.
- 653 6. GBD Tuberculosis Collaborators. Global, regional, and national burden of tuberculosis,
654 1990–2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study.
655 *Lancet Infect Dis* 2018; 18(12):1329–49.
- 656 7. Dye C, Glaziou P, Floyd K, Raviglione M. Prospects for tuberculosis elimination. *Annu Rev*
657 *Public Health* 2013; 34:271–86.
- 658 8. WHO. End TB Strategy: Global strategy and targets for tuberculosis prevention, care and
659 control after 2015; 2015.
- 660 9. Lonnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis
661 epidemics: The role of risk factors and social determinants. *Social Science & Medicine* 2009;
662 2009 (68):2240–6.
- 663 10. Divangahi M, editor. The New Paradigm of Immunity to Tuberculosis. New York, NY:
664 Springer New York; 2013. (vol 783).
- 665 11. Keshavjee S, Amanullah F, Cattamanchi A, Chaisson R, Dobos KM, Fox GJ et al. Moving
666 toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics
667 for Tuberculosis Infection. *Am J Respir Crit Care Med* 2019; 199(5):564–71.
- 668 12. Esmail H, Barry CE, Young DB, Wilkinson RJ. The ongoing challenge of latent
669 tuberculosis. *Philos Trans R Soc Lond B Biol Sci* 2014; 369(1645):20130437.
- 670 13. Diel R, Loddenkemper R, Zellweger J-P, Sotgiu G, D'Ambrosio L, Centis R et al. Old ideas
671 to innovate tuberculosis control: preventive treatment to achieve elimination. *Eur. Respir J*
672 2013; 42(3):785–801.
- 673 14. Burki T. Tuberculosis post-2015: looking to the future with optimism. *Lancet Infect Dis*
674 2015; 15(1):21–2.
- 675 15. Fullman N, Yearwood J, Solomon M Abay, Cristiana Abbafati, Foad Abd-Allah, Jemal
676 Abdela et al. Measuring performance on the Healthcare Access and Quality Index for 195
677 countries and territories and selected subnational locations: a systematic analysis from the
678 Global Burden of Disease Study 2016. *Lancet* 2018; 391(10136):2236–71.
- 679 16. Pai M, Memish ZA. New tuberculosis tools are here: can we deliver them for maximal
680 impact? *J Epidemiol Glob Health* 2013; 3(1):1–2.
- 681 17. Lönnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P et al. Tuberculosis
682 control and elimination 2010–50: cure, care, and social development. *Lancet* 2010; 375 (9728):
683 1814–29.
- 684 18. Al Yaquobi F, Al-Abri S, Al-Abri B, Al-Abaidani I, Al-Jardani A, D'Ambrosio L et al. Tu-
685 tuberculosis elimination: a dream or a reality? The case of Oman. *Eur Respir J* 2018; 51(1):1–3.

- 686 19. Voniatis C, Migliori GB, Voniatis, Georgiou A, D'Ambrosio L, Rosella Centis and Mario
687 C. Raviglione. Tuberculosis elimination: dream or reality? The case of Cyprus. *Eur Respir J*
688 2014; 44(2):540–3.
- 689 20. Migliori GB, Raviglione MC, editors. *Essential Tuberculosis*. Cham: Springer International
690 Publishing; 2021.
- 691 21. Lienhardt C, Lönnroth K, Menzies D, Balasegaram M, Chakaya J, Cobelens F et al.
692 *Translational Research for Tuberculosis Elimination: Priorities, Challenges, and Actions*. *PLoS*
693 *Med* 2016; 13(3):e1001965.
- 694 22. Glaziou P, Falzon D, Floyd K, Raviglione M. Global epidemiology of tuberculosis. *Semin*
695 *Respir Crit Care Med* 2013; 34(1):3–16.
- 696 23. Duarte R, Migliori GB, Zumla A, Cordeiro CR. Strengthening tuberculosis control to
697 advance towards elimination: The 2018 Rev. *Port. Pneumol. (RPP) TB Series*. *Pulmonology*
698 2018; 24(2):67–8.
- 699 24. Goosby E, Jamison D, Swaminathan S, Reid M, Zuccala E. The Lancet Commission on
700 tuberculosis: building a tuberculosis-free world. *Lancet* 2018; 391(10126):1132–3.
- 701 25. WHO. *Global Strategy for Tuberculosis Research: RESEARCH AND INNOVATION*;
702 2020.
- 703 26. Harris RC, Sumner T, Knight GM, Zhang H, White RG. Potential impact of tuberculosis
704 vaccines in China, South Africa, and India. *Sci Transl Med* 2020; 12(564).
- 705 27. Schragger LK, Vekemens J, Drager N, Lewinsohn DM, Olesen OF. The status of tuberculosis
706 vaccine development. *Lancet Infect Dis* 2020; 20(3):e28–e37.
- 707 28. Georghiou L, Harper JC, Miles I, Kennan M, Popper R, editors. *The handbook of*
708 *Technology Foresight: Concepts and Practice*. Northampton MA USA: Edward Elgar Pub; 2009.
- 709 29. Cabral, B. P, Fonseca M, Mota F. What is the future of cancer care? A technology foresight
710 assessment of experts' expectations. *Economics of Innovation and New Technology* 2019; 28.
- 711 30. Haghdoost A, Pourhosseini SS, Emami M, Dehnavieh R, Barfeh T, Mehrolhassani MH.
712 *Foresight in health sciences using CLA method*. *Med J Islam Repub Iran* 2017; 31:1–8.
- 713 31. Martin B. R. The origins of the concept of 'foresight' in science and technology: An
714 insider's perspective. *Technological Forecasting and Social Change* 2010; 77(9):1438–47.
- 715 32. Miles I. The development of technology foresight: A review. *Technological Forecasting and*
716 *Social Change* 2010; 77(9):1448–56.
- 717 33. Zackiewicz M., Salles-Filho S. *Technological Foresight: Um instrumento para política*
718 *científica e tecnológica [Estudos Prospectivos]*. *PARCERIAS ESTRATÉGICAS* 2001; 10 -
719 *March* 2001:144–61.
- 720 34. Ingelstam L. (Long term science policy: a limited vision: Research Foresight: priority
721 setting in science [Ben Martin and John Irvine]. *Futures* 1991:211–3.
- 722 35. Dosi G, Soete L, C.R. Freeman, Nelson RR, editors *Technical Change and Economic*
723 *Theory*; 1988.
- 724 36. Linstone HA. Three eras of technology foresight. *Technovation* 2011; 31(2-3):69–76.
- 725 37. Zackiewicz M, Sales-Filho S. *Estudos Prospectivos: Technology Foresight - Um instrumento*
726 *para política científica e tecnológica Março/2001; (PARCERIAS ESTRATÉGICAS número*
727 *10)*.

- 728 38. Zenteno-Cuevas R. Successes and failures in human tuberculosis vaccine development.
729 *Expert Opin Biol Ther* 2017; 17(12):1481–91.
- 730 39. Pai M, Behr MA, Dowdy D, Boehme CC, Ann Ginsberg⁶ Soumya Swaminathan⁷, Melvin
731 Spigelman⁸ Haileyesus Getahun⁹. Tuberculosis. *Nature Reviews* 2016:1–23.
- 732 40. Kuhn TS, editor. *A Estrutura das revolucoes cientificas* 1989. São Paulo: Perspectiva; 1998.
- 733 41. Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini IM, Dye C et al.
734 Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. *Proc*
735 *Natl Acad Sci U S A* 2009; 106(33):13980–5.
- 736 42. Gupta S, Kakkar V. Recent technological advancements in tuberculosis diagnostics - A
737 review. *Biosens Bioelectron* 2018; 115:14–29.
- 738 43. Schragger kl, Harris RC, Vekemans j¹². Research and development of new tuberculosis
739 vaccines: a review. *F1000RESEARCH* 2018.
- 740 44. Bonaccorsi A, Apreda R, Fantoni G. Expert biases in technology foresight. Why they are a
741 problem and how to mitigate them. *Technological Forecasting and Social Change* 2020; 151:1-
742 17.
- 743 45. Bolger F, Wright G. Use of expert knowledge to anticipate the future: Issues, analysis and
744 directions. *International Journal of Forecasting* 2017; 33(1):230–43.
- 745 46. MacGregor-Fairlie M, Wilkinson S, Besra GS, Goldberg Oppenheimer P. Tuberculosis
746 diagnostics: overcoming ancient challenges with modern solutions. *Emerg Top Life Sci* 2020;
747 4(4):423–36.
- 748 47. Working Group on New TB Drugs. Global TB new drugs pipeline. Stop TB partnership;
749 2022. Available from: URL: <https://www.newtbdrugs.org/pipeline/clinical>.
- 750 48. Lundvall B-Å. National Innovation Systems—Analytical Concept and Development Tool.
751 *Industry and Innovation* 2007; 14(1):95–119.
- 752 49. Edquist C. The Systems of Innovation Approach and Innovation Policy: An account of the
753 state of the art. Aalborg; 2001. Available from: URL: [http://www.tema.liu.se/tema-](http://www.tema.liu.se/tema-t/sirp/chaed.htm)
754 [t/sirp/chaed.htm](http://www.tema.liu.se/tema-t/sirp/chaed.htm).
- 755 50. Dosi G. Technological paradigms and technological trajectories: A suggested interpretation
756 of determinants and directions of technical change. *revista brasileira de inovação* 1982:17–32.
- 757 51. Rosemberg N. Quão Exógena é a ciência? *revista brasileira de inovação* 2006;
758 2006/5(2):245-271.
- 759 52. HUSSEY G. Pipeline Report 2021: Tuberculosis vaccines.
- 760 53. Li JF, Garnsey E. Policy-driven ecosystems for new vaccine development. *Technovation*
761 2014; 34(12):762–72.
- 762 54. Kaufmann SHE. Learning from natural infection for rational tuberculosis vaccine
763 design:From basic science to trans 2010.
- 764 55. Kaufmann SHE. Future vaccination strategies against tuberculosis: thinking outside the box.
765 *Immunity* 2010; 33(4):567–77.
- 766 56. WHO. consolidated guidelines on tuberculosis: Rapid diagnostics for tuberculosis detection;
767 Module 3: Diagnosis. Geneva, Switzerland: World Health Organization.
- 768 57. WHO. consolidated guidelines on tuberculosis: Rapid diagnostics for tuberculosis detection;
769 Module 3: Diagnosis. Geneva, Switzerland: World Health Organization.

- 770 58. Miller BS, Gliddon HD, McKendry RA. Towards a Future of Rapid, Low-Cost, Multiplexed
771 Detection of Antimicrobial Resistance Markers for Tuberculosis and Other Pathogens. Clin
772 Chem 2019; 65(3):367–9.
- 773 59. WHO. Rapid communication: TB antigen-based skin tests for the diagnosis of TB infection.
774 WHO; 2022.
- 775 60. Darboe F, Mbandi S, Thompson EG, Fisher M, Rodo M, van Rooyen M et al. Diagnostic
776 performance of an optimized transcriptomic signature of risk of tuberculosis in cryopreserved
777 peripheral blood mononuclear cells. Tuberculosis (Edinb) 2018; 108:124–6.
- 778 61. Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM et al. A blood
779 RNA signature for tuberculosis disease risk: a prospective cohort study. The Lancet 2016;
780 387(10035):2312–22.
- 781 62. Levin M, Kaforou M. Predicting active tuberculosis progression by RNA analysis. The
782 Lancet 2016; 387(10035):2302–11. Available from: URL: [http://dx.doi.org/10.1016/S0140-](http://dx.doi.org/10.1016/S0140-6736(16)00165-3)
783 [6736\(16\)00165-3](http://dx.doi.org/10.1016/S0140-6736(16)00165-3).
- 784 63. MacLean E, Broger T. A 10-Gene Signature for the Diagnosis and Treatment Monitoring of
785 Active Tuberculosis Using a Molecular Interaction Network Approach. EBioMedicine 2017;
786 15:112–26.




Figure 1 - strategies




Figure 2 - Technologies




Figure 3 - Vaccines




Figure 4 - diagnostics tests